US4942182A - Treatment for cocaine addiction - Google Patents
Treatment for cocaine addiction Download PDFInfo
- Publication number
- US4942182A US4942182A US07/317,405 US31740589A US4942182A US 4942182 A US4942182 A US 4942182A US 31740589 A US31740589 A US 31740589A US 4942182 A US4942182 A US 4942182A
- Authority
- US
- United States
- Prior art keywords
- carbamazepine
- cocaine
- treatment
- seizures
- blocking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Definitions
- This invention provides a means of treating cocaine addiction by chronic oral administration of carbamazepine. While it had previously been reported that administration of carbamazepine would prevent epileptic and lidocaine-induced seizures, the use of this medication to overcome toxic and habituating action of cocaine had not previously been known.
- Cocaine abuse has become a major public health problem in recent years as more reinforcing forms of the drug have become available. Acute intoxication from cocaine is marked by convulsions and cardiac arrhythmias, and chronic cocaine use can be associated with increasing behavioral pathology and toxicity. The mechanisms underlying the reinforcing and toxic effects of cocaine are not fully understood, particularly since cocaine has dual actions as a potentiator of catecholaminergic systems; in particular, the dopamine system, and as a local anesthetic. Although dopaminergic antagonists have shown some success in blocking the reinforcing effects of cocaine in experimental animals, there is, at present, no pharmacological treatment that is efficacious and acceptable to patients.
- Carbamazepine is a major antiepileptic drug that has also been shown to be effective in the treatment of manic-depressive disorder. Recent studies in the Biological Psychiatry Branch have shown that chronic carbamazepine is extremely effective in preventing cocaine-induced seizures and deaths in rats.
- Carbamazepine is an iminostilbene derivative that is used clinically to treat seizure disorders, trigeminal neuralgia, and, most recently, manicdepressive illness. Carbamazepine is very effective as an anticonvulsant in several experimental seizure paradigms including amygdala kindling, alcohol withdrawal, and maximal electroconvulsive shock, but is less effective on seizures induced by pentylenetetrazole and high-dose picrotoxin. The effectiveness of anticonvulsants has been shown to depend upon the stage of evolution of the seizure process. For example, carbamazepine suppresses completed amygdala-kindled seizures in rats, but is ineffective in preventing their development.
- Lidocaine is a local anesthetic that can be used to kindle seizures when given repeatedly in large, but initially subconvulsant, doses. This process has been called pharmacological kindling. Local anesthetic seizures resemble those produced by electrical kindling of the amygdala in that there is a prominent facial component, clonic jerking of the forepaws, and electroencephalographic evidence of seizure activity in the amygdala. In addition, the lidocaine seizures have been shown to increase glucose utilization in the amygdala, hippocampus, and perirhinal cortex.
- Cocaine is equipotent to lidocaine as a local anesthetic, but additionally has psychomotor stimulant properties that are thought to result from its ability to block catecholamine reuptake. Repeated administration of low to moderate doses of cocaine induces increased motor activation and stereotypy, a process called behavioral sensitization or reverse tolerance. This aspect of cocaine's effect appears closely related to its psychomotor stimulant properties, as similar behavioral changes are not seen with repeated lidocaine administration, but are observed with other psychomotor stimulants; e.g., amphetamine. Repeated administration of high doses of cocaine results in the progressive development of seizures which follow a time course akin to kindling.
- carbamazepine is an appropriate method for treatment of habituation by blocking reinforcing properties of cocaine and for relief of toxic responses to cocaine such as panic attacks.
- the carbamazepine must be administered chronically to maintain a relatively constant blood level. Doses ranging from 200-2000 mg/day will usually result in a blood level of 4-12 ⁇ g/ml. The drug must be given when the patient is relatively drug free. This is because the use of carbamazepine appears at times to worsen seizures and increase lethal effects of cocaine when given acutely near the time cocaine is administered.
- compositions for administration may contain therein the usual fillers known in the pharmaceutical art.
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/317,405 US4942182A (en) | 1989-03-01 | 1989-03-01 | Treatment for cocaine addiction |
| EP19900904570 EP0479786A4 (en) | 1989-03-01 | 1990-03-01 | Treatment for cocaine addiction |
| AU51844/90A AU623984B2 (en) | 1989-03-01 | 1990-03-01 | Treatment for cocaine addiction |
| CA002048609A CA2048609A1 (en) | 1989-03-01 | 1990-03-01 | Treatment for cocaine addiction |
| PCT/US1990/001059 WO1990010446A1 (en) | 1989-03-01 | 1990-03-01 | Treatment for cocaine addiction |
| JP2504446A JPH072639B2 (en) | 1989-03-01 | 1990-03-01 | Cocaine addiction remedy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/317,405 US4942182A (en) | 1989-03-01 | 1989-03-01 | Treatment for cocaine addiction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US4942182A true US4942182A (en) | 1990-07-17 |
Family
ID=23233499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/317,405 Expired - Lifetime US4942182A (en) | 1989-03-01 | 1989-03-01 | Treatment for cocaine addiction |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4942182A (en) |
| EP (1) | EP0479786A4 (en) |
| JP (1) | JPH072639B2 (en) |
| AU (1) | AU623984B2 (en) |
| CA (1) | CA2048609A1 (en) |
| WO (1) | WO1990010446A1 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5102913A (en) * | 1991-07-01 | 1992-04-07 | Halikas James A | Treatment for cocaine use employing valproic acid |
| US5321012A (en) * | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
| US5326570A (en) * | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
| US5824684A (en) * | 1997-02-21 | 1998-10-20 | Synapse Pharmaceuticals International, Inc. | Method for treating drug and alcohol addiction |
| US7041320B1 (en) | 2002-05-31 | 2006-05-09 | Biotek, Inc. | High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence |
| USRE39300E1 (en) | 1993-01-28 | 2006-09-19 | Virginia Commonwealth University Medical College Of Virginia | Inhibiting the development of tolerance to and/or dependence on an addictive substance |
| US7157102B1 (en) | 2002-05-31 | 2007-01-02 | Biotek, Inc. | Multi-layered microcapsules and method of preparing same |
| WO2006116148A3 (en) * | 2005-04-22 | 2008-09-12 | Wyeth Corp | (7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2104006C1 (en) * | 1997-02-14 | 1998-02-10 | Олег Ильич Эпштейн | Method of drug addiction treatment |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH649080A5 (en) * | 1981-04-16 | 1985-04-30 | Ciba Geigy Ag | 5H-DIBENZ (B, F) AZEPINE-5-CARBOXAMIDES AS A MEDICINE FOR PROPHYLAXIS AND TREATMENT OF CEREBRAL PERFORMANCE INSUFFICIENCY. |
-
1989
- 1989-03-01 US US07/317,405 patent/US4942182A/en not_active Expired - Lifetime
-
1990
- 1990-03-01 WO PCT/US1990/001059 patent/WO1990010446A1/en not_active Ceased
- 1990-03-01 JP JP2504446A patent/JPH072639B2/en not_active Expired - Lifetime
- 1990-03-01 CA CA002048609A patent/CA2048609A1/en not_active Abandoned
- 1990-03-01 EP EP19900904570 patent/EP0479786A4/en not_active Ceased
- 1990-03-01 AU AU51844/90A patent/AU623984B2/en not_active Ceased
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5102913A (en) * | 1991-07-01 | 1992-04-07 | Halikas James A | Treatment for cocaine use employing valproic acid |
| US5326570A (en) * | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
| US5912013A (en) * | 1991-07-23 | 1999-06-15 | Shire Laboratories, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
| US5321012A (en) * | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
| USRE39300E1 (en) | 1993-01-28 | 2006-09-19 | Virginia Commonwealth University Medical College Of Virginia | Inhibiting the development of tolerance to and/or dependence on an addictive substance |
| US5824684A (en) * | 1997-02-21 | 1998-10-20 | Synapse Pharmaceuticals International, Inc. | Method for treating drug and alcohol addiction |
| US7041320B1 (en) | 2002-05-31 | 2006-05-09 | Biotek, Inc. | High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence |
| US7157102B1 (en) | 2002-05-31 | 2007-01-02 | Biotek, Inc. | Multi-layered microcapsules and method of preparing same |
| WO2006116148A3 (en) * | 2005-04-22 | 2008-09-12 | Wyeth Corp | (7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1990010446A1 (en) | 1990-09-20 |
| CA2048609A1 (en) | 1990-09-02 |
| AU623984B2 (en) | 1992-05-28 |
| JPH072639B2 (en) | 1995-01-18 |
| JPH04503805A (en) | 1992-07-09 |
| AU5184490A (en) | 1990-10-09 |
| EP0479786A4 (en) | 1992-09-30 |
| EP0479786A1 (en) | 1992-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69428523T2 (en) | METHOD FOR TREATING MENTAL OR MENTAL DISEASES AND MENTAL OR MENTAL DISEASES ASSOCIATED WITH SEASON | |
| DE69929041T2 (en) | USE OF CABERGOLIN FOR THE TREATMENT OF "RESTLESS LEGS SYNDROME" | |
| DE69805202T2 (en) | USE OF BENZHYDRYLSULFINYL DERIVATIVES FOR TREATING THE SLEEPNESS DRUG-ORIGINAL ORIGIN | |
| Wright | Pharmacologic effects of ketamine and its use in veterinary medicine | |
| Hoaken et al. | Drugs of abuse and the elicitation of human aggressive behavior | |
| EP2201943B1 (en) | Novel use of a peptide class of compounds for treating diabetic neuropathic pain | |
| DE69133136T2 (en) | MICROCAPSULES WITH CONTROLLED RELEASE AND THEIR USE FOR STIMULATING NERVOUS FIBER GROWTH | |
| DE69927496T2 (en) | PAIN RELIEF WITH ENDOGENIC CANNABINOIDS | |
| HUE033180T2 (en) | Peptide compounds for treating refractory status epilepticus | |
| Criswell et al. | Long-term D1-dopamine receptor sensitization in neonatal 6-OHDA-lesioned rats is blocked by an NMDA antagonist | |
| AU623984B2 (en) | Treatment for cocaine addiction | |
| WO2002058688A1 (en) | Use of neurotoxic substances in producing a medicament for treating joint pains | |
| Frey et al. | Effect of psychotropic agents on a model of absence epilepsy in rats | |
| Kocher | The use of psychotropic drugs in the treatment of cancer pain | |
| Lyttkens et al. | Local anaesthetics and tinnitus: proposed peripheral mechanism of action of lidocaine | |
| DE60100660T2 (en) | USE OF MODAFINIL FOR PRODUCING A MEDICINAL PRODUCT FOR TREATING VIGILANCE DISORDERS RELATED TO MYOPATHIA | |
| US4355027A (en) | Process and composition for treating disorders by administering piracetam and choline | |
| DE19941217A1 (en) | Treatment of migraines by administration of alpha-lipoic acid or derivatives thereof | |
| Hyde et al. | Acetylcholine and convulsive activity | |
| EP0147185A2 (en) | Therapeutic use of cytidyl disphosphocholine to increase neuronal acetylcholine | |
| WO2006015590A2 (en) | Novel formulation for l-tryptophane comprising carbidopa/benserazide | |
| DaVanzo et al. | Studies on the mechanism of action of aminooxyacetic acid: I. Reversal of aminooxyacetic acid-induced convulsions by various agents | |
| Trabert et al. | A seizure, and electroencephalographic signs of a lowered seizure threshold, associated with fluvoxamine treatment of obsessive-compulsive disorder | |
| US5102913A (en) | Treatment for cocaine use employing valproic acid | |
| US6514999B1 (en) | Use of an agent for treating the symptoms of Parkinson's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: UNITED STATES OF AMERICA, THE, AS REPRESENTED BY T Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:WEISS, SUSAN R. B.;POST, ROBERT M.;AIGNER, THOMAS G.;REEL/FRAME:005196/0287 Effective date: 19890801 |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| CC | Certificate of correction | ||
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| REMI | Maintenance fee reminder mailed | ||
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| SULP | Surcharge for late payment | ||
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| FPAY | Fee payment |
Year of fee payment: 12 |
|
| REMI | Maintenance fee reminder mailed |